Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications
نویسندگان
چکیده
Authorship guidelines have established criteria to guide author selection based on significance of contribution and helped to define associated responsibilities and accountabilities for the published findings. However, low awareness, variable interpretation, and inconsistent application of these guidelines can lead to confusion and a lack of transparency when recognizing those who merit authorship. This article describes a research project led by the Medical Publishing Insights and Practices (MPIP) Initiative to identify current challenges when determining authorship for industry-sponsored clinical trials and develop an improved approach to facilitate decision-making when recognizing authors from related publications. A total of 498 clinical investigators, journal editors, publication professionals and medical writers were surveyed to understand better how they would adjudicate challenging, real-world authorship case scenarios, determine the perceived frequency of each scenario and rate their confidence in the responses provided. Multiple rounds of discussions about these results with journal editors, clinical investigators and industry representatives led to the development of key recommendations intended to enhance transparency when determining authorship. These included forming a representative group to establish authorship criteria early in a trial, having all trial contributors agree to these criteria and documenting trial contributions to objectively determine who warrants an invitation to participate in the manuscript development process. The resulting Five-step Authorship Framework is designed to create a more standardized approach when determining authorship for clinical trial publications. Overall, these recommendations aim to facilitate more transparent authorship decisions and help readers better assess the credibility of results and perspectives of the authors for medical research more broadly. Please see related article: http://www.biomedcentral.com/1741-7015/12/214.
منابع مشابه
Enhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative.
One expected consequence of increased transparency surrounding clinical trials is that journals will experience a significant growth in the number of manuscript submissions from industry-sponsored research, particularly manuscripts reporting the results of early-phase research. This increase could be substantial since, until recently, about 90% of Phase I studies and 60% of Phase II studies wer...
متن کاملGhost Authorship in Industry-Initiated Randomised Trials
BACKGROUND Ghost authorship, the failure to name, as an author, an individual who has made substantial contributions to an article, may result in lack of accountability. The prevalence and nature of ghost authorship in industry-initiated randomised trials is not known. METHODS AND FINDINGS We conducted a cohort study comparing protocols and corresponding publications for industry-initiated tr...
متن کاملAlong with the privilege of authorship come important responsibilities
Transparently documenting who and why a person is an author of a clinical trial report, as with any other article, is important since it allows research team members appropriate recognition and also likely helps reduce or avoid problems such as ghost authorship. Marušić and colleagues have previously proposed a five-step framework for attributing authorship of pharmaceutical company-sponsored c...
متن کاملResult Publication of Chinese Trials in World Health Organization Primary Registries
BACKGROUND Result publication is the key step to improve the transparency of clinical trials. OBJECTIVE To investigate the result publication rate of Chinese trials registered in World Health Organization (WHO) primary registries. METHOD We searched 11 WHO primary registries for Chinese trials records. The progress of each trial was analyzed. We searched for the full texts of result publica...
متن کاملPrevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.
OBJECTIVE The literature continues to highlight the debate on the ethics and merits of trials sponsored by the pharmaceutical industry. This study attempts to determine the prevalence and outcomes of industry-sponsored trials involving clozapine, risperidone, or olanzapine. METHODS We searched the literature from January 1, 1990, to December 31, 2001, to capture all eligible clinical trials i...
متن کامل